Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Publikation

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Wissenschaftlicher Artikel/Review - 17.04.2018

Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Docampo Lara Carmen Iglesias, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Lynch Mark, Jayaprakash Vijayvel, Li Li, Gillison Maura L

Zitation

Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison M. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018; 81:45-51.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Oral Oncol 2018; 81

Veröffentlichungsdatum

17.04.2018

eISSN (Online)

1879-0593

Seiten

45-51

Kurzbeschreibung/Zielsetzung

We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory squamous cell carcinoma of the head and neck (SCCHN).